The role of maternal blood elabela levels in the prediction of placenta previa and accreta

IF 3 2区医学 Q2 DEVELOPMENTAL BIOLOGY

Placenta Pub Date : 2025-01-01 DOI:10.1016/j.placenta.2024.12.001

Ömer Demir , Miraç Özalp , Hüseyin Yaman , Fatih Mehmet Fındık

{"title":"The role of maternal blood elabela levels in the prediction of placenta previa and accreta","authors":"Ömer Demir , Miraç Özalp , Hüseyin Yaman , Fatih Mehmet Fındık","doi":"10.1016/j.placenta.2024.12.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Placenta previa and Placenta Accreta Spectrum are life-threatening obstetric conditions that are challenging to diagnose accurately. Currently, there is no biochemical parameter available for their diagnosis. The aim of our study is to investigate the potential of Elabela as a laboratory marker that could predict placenta previa and placenta accreta, both of which can lead to severe, life-threatening complications for the mother.</div></div><div><h3>Methods</h3><div>In this study, which was conducted prospectively in two tertiary centers between 2020 and 2022, Elabela levels were examined in patient groups with placental insertion and invasion anomalies. SPSS program was used for comparative statistical analysis between groups.</div></div><div><h3>Results</h3><div>Of the 67 analyzed patients, 32 were in the control group, 12 were in the previa group, and 23 were in the accreta group. There was no statistically significant difference between the groups regarding age, BMI, number of curettages, presence of previous cesarean section, and smoking status. The Elabela level was measured at 135.6 ± 72.1 in the control group, 988.3 ± 925.5 in the previa group, and 376 ± 364.6 in the accreta group, with a statistically significant difference between the groups. The cut-off value of Elabela levels in the previa group was determined to be 304, with a sensitivity of 83.30 % and a specificity of 83.60 % (AUC = 0.909). In the accreta group, the cut-off value was 195.5, with a sensitivity of 60.90 % and a specificity of 61.40 % (AUC = 0.658).</div></div><div><h3>Discussion</h3><div>By showing that the prediction of placenta previa and placenta acreata can be made with a biochemical parameter in our study, young researchers will focus more on this subject and thus make many contributions to science.</div></div>","PeriodicalId":20203,"journal":{"name":"Placenta","volume":"159 ","pages":"Pages 70-75"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Placenta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0143400424007896","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DEVELOPMENTAL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Placenta previa and Placenta Accreta Spectrum are life-threatening obstetric conditions that are challenging to diagnose accurately. Currently, there is no biochemical parameter available for their diagnosis. The aim of our study is to investigate the potential of Elabela as a laboratory marker that could predict placenta previa and placenta accreta, both of which can lead to severe, life-threatening complications for the mother.

Methods

In this study, which was conducted prospectively in two tertiary centers between 2020 and 2022, Elabela levels were examined in patient groups with placental insertion and invasion anomalies. SPSS program was used for comparative statistical analysis between groups.

Results

Of the 67 analyzed patients, 32 were in the control group, 12 were in the previa group, and 23 were in the accreta group. There was no statistically significant difference between the groups regarding age, BMI, number of curettages, presence of previous cesarean section, and smoking status. The Elabela level was measured at 135.6 ± 72.1 in the control group, 988.3 ± 925.5 in the previa group, and 376 ± 364.6 in the accreta group, with a statistically significant difference between the groups. The cut-off value of Elabela levels in the previa group was determined to be 304, with a sensitivity of 83.30 % and a specificity of 83.60 % (AUC = 0.909). In the accreta group, the cut-off value was 195.5, with a sensitivity of 60.90 % and a specificity of 61.40 % (AUC = 0.658).

Discussion

By showing that the prediction of placenta previa and placenta acreata can be made with a biochemical parameter in our study, young researchers will focus more on this subject and thus make many contributions to science.

查看原文本刊更多论文

母体血elabela水平在预测前置胎盘和增生胎盘中的作用。

前置胎盘和胎盘增生谱系是危及生命的产科条件是具有挑战性的准确诊断。目前，没有可用于诊断的生化参数。我们研究的目的是研究Elabela作为实验室标记物的潜力，可以预测前置胎盘和胎盘增生，这两种情况都可能导致母亲严重的、危及生命的并发症。方法：本研究于2020年至2022年期间在两家三级中心进行前瞻性研究，检测胎盘插入和侵入异常患者组的Elabela水平。采用SPSS软件进行组间比较统计分析。结果：67例患者中，对照组32例，previa组12例，accreta组23例。两组在年龄、BMI、刮宫次数、是否有剖宫产史和吸烟状况方面无统计学差异。对照组Elabela水平为135.6±72.1，previa组为988.3±925.5，accreta组为376±364.6，组间差异有统计学意义。前via组Elabela水平的临界值为304，敏感性为83.30%，特异性为83.60% （AUC = 0.909）。accreta组的临界值为195.5，敏感性为60.90%，特异性为61.40% （AUC = 0.658）。讨论：通过我们的研究表明，可以用一个生化参数来预测前置胎盘和胎盘增生，这将使年轻的研究人员更加关注这一主题，从而为科学做出许多贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Placenta 医学-发育生物学

CiteScore

6.30

自引率

10.50%

发文量

391

审稿时长

78 days

期刊介绍： Placenta publishes high-quality original articles and invited topical reviews on all aspects of human and animal placentation, and the interactions between the mother, the placenta and fetal development. Topics covered include evolution, development, genetics and epigenetics, stem cells, metabolism, transport, immunology, pathology, pharmacology, cell and molecular biology, and developmental programming. The Editors welcome studies on implantation and the endometrium, comparative placentation, the uterine and umbilical circulations, the relationship between fetal and placental development, clinical aspects of altered placental development or function, the placental membranes, the influence of paternal factors on placental development or function, and the assessment of biomarkers of placental disorders.